Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Cardiovasc Electrophysiol ; 31(6): 1298-1306, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32270566

RESUMEN

INTRODUCTION: This study aimed to compare touch-up ablation (TUA) rates and pulmonary vein isolation (PVI) durability of hot balloon ablation (HBA) and cryoballoon ablation (CBA) in paroxysmal atrial fibrillation (PAF) patients. METHODS: In total, 137 PAF patients were enrolled in the study. Among them, 59 underwent two HBA procedures at 6-month intervals and 78 patients underwent two CBA sessions, both regardless of atrial fibrillation recurrence. Propensity score matching was performed to estimate similar patient characteristics between the HBA and CBA groups. RESULTS: Each group comprised of 46 matched patients for comparison. The TUA rate at the first session was higher for HBA (49 of 184 PVs) than for CBA (20 PVs) (P = .01), with the highest incidence at the left superior pulmonary vein (LSPV). The rates of PVI durability at the second session performed 7 months later were similar between HBA (168 of 184 PVs) and CBA (162 PVs) groups. The PVI durability rate at the TUA sites of the first session was higher for HBA than for CBA (41 of 49 PVs vs 10 PVs, respectively; P = .01). Fifty percent of the patients underwent HBA at 73°C for the LSPV. HBA performed at 73°C yielded a lower TUA rate than that at 70°C (16 of 23 PVs vs 7 of 23 PVs; P = .008). CONCLUSIONS: While PVI durability was similar between HBA and CBA, the TUA rate was higher for HBA than for CBA, especially on the LSPV. For LSPV, HBA at a balloon temperature of 73°C may reduce the TUA rate.


Asunto(s)
Fibrilación Atrial/cirugía , Ablación por Catéter , Criocirugía , Calor/uso terapéutico , Venas Pulmonares/cirugía , Potenciales de Acción , Anciano , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/fisiopatología , Catéteres Cardíacos , Ablación por Catéter/efectos adversos , Ablación por Catéter/instrumentación , Criocirugía/efectos adversos , Criocirugía/instrumentación , Femenino , Frecuencia Cardíaca , Calor/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Venas Pulmonares/fisiopatología , Recurrencia , Reoperación , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
2.
J Arrhythm ; 36(1): 95-104, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32071627

RESUMEN

BACKGROUND: Different subtypes of ischemic stroke may have different risk factors, clinical features, and prognoses. This study investigated the incidence and mode of stroke recurrence in patients with a history of stroke who underwent atrial fibrillation (AF) ablation. METHODS: Of 825 patients who underwent AF ablation from 2006 to 2016, 77 patients (9.3%, median age 69 years) with a prior ischemic stroke were identified. Patients were classified as those with prior cardioembolic (CE) stroke (n = 55) and those with prior non-CE stroke (n = 22). The incidence and pattern of stroke recurrence were investigated. RESULTS: The incidence of asymptomatic AF (54.5% vs 22.7%; P = .011) and left atrial volume (135.8 mL vs 109.3 mL; P = .024) was greater in the CE group than in the non-CE group. Anticoagulation treatment was discontinued at an average of 28.1 months following the initial ablation in 34 (44.2%) patients. None of the patients developed CE stroke during a median 4.1-year follow-up. In the non-CE group, 2 patients experienced recurrent non-CE stroke (lacunar infarction in 1 and atherosclerotic stroke in 1); however, AF was not observed at the onset of recurrent ischemic stroke. CONCLUSIONS: In patients with a history of stroke who underwent catheter ablation for AF, the incidence of recurrent stroke was 0.54/100 patient-years. The previous stroke in these patients may not have been due to AF in some cases; therefore, a large-scale prospective study is warranted to identify the appro priate antithrombotic therapy for the prevention of potentially recurrent stroke.

3.
Eur Heart J Case Rep ; 3(2)2019 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-31449600

RESUMEN

BACKGROUND: Cardiac involvement by malignant lymphocytic neoplasms is a rare phenomenon. Little is known concerning cardiotoxicity in the chronic phase after completion of treatment. CASE SUMMARY: A 50-year-old woman with a past history of cardiac involvement of acute lymphoblastic leukaemia (ALL) underwent electrophysiologic study and catheter ablation for symptomatic atrial tachycardia (AT). She was diagnosed with ALL when she was 8 years old and treated with systematic chemotherapy with prednisolone and vincristine. After complete remission, she suffered from repeated palpitations beginning at the age of 16 years. Electrophysiologic study using high-density (HD) mapping showed two types of peritricuspid AT in addition to low voltage in the right atrium with conduction delay. DISCUSSION: Cardiac involvement by malignant lymphocytic neoplasms is a rare phenomenon, and cardiac infiltration often disappears after remission of ALL. Thus, little is known about cardiac electrophysiological characteristics in the chronic phase of complete remission of ALL. We describe a rare case of a patient with multiple peritricuspidal reentry tachycardias after cardiac infiltration by leukaemia using a HD mapping system.

4.
J Interv Card Electrophysiol ; 54(3): 209-215, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30460587

RESUMEN

PURPOSE: Our aim was to elucidate the relationship between obstructive sleep apnea (OSA) and atrial fibrillation (AF) recurrence after repeated pulmonary vein isolation (PVI). METHODS: We conducted a non-randomized observational study, with the data prospectively collected. One hundred patients (paroxysmal AF, n = 89) underwent PVI using a contact force-sensing catheter. All patients underwent an electrophysiological study and additional ablation for left atrium-pulmonary vein (PV) reconnection and non-PV foci, 6 months after the first treatment session, regardless of AF recurrence. Those with an apnea-hypopnea index ≥ 15 were diagnosed with OSA. Continuous positive air pressure (CPAP) therapy was initiated after the second treatment session, based on results of a sleep study. For analysis, patients were classified into the non-OSA (n = 66), treated OSA (OSA patients undergoing CPAP; n = 11), and untreated OSA (n = 23) groups, and between-group differences evaluated. RESULTS: After the first session, AF recurrence was observed in 18.2% (12/66) and 14.7% (5/34) of patients without and with OSA, respectively (P = 0.678). After the second procedure, the rate of AF recurrence was 12.1% (8/66) in the non-OSA group, 9.1% (1/11) in the treated OSA group, and 8.7% (2/23) in the untreated OSA group (log-rank P = 0.944). CONCLUSIONS: The rate of AF recurrence might not be greater in patients with untreated OSA than in those without OSA and those with treated OSA after repeated PVI, using a contact force-sensing catheter, for patients with paroxysmal or short-term persistent AF.


Asunto(s)
Fibrilación Atrial/cirugía , Ablación por Catéter/métodos , Venas Pulmonares/cirugía , Apnea Obstructiva del Sueño/complicaciones , Anciano , Presión de las Vías Aéreas Positiva Contínua , Técnicas Electrofisiológicas Cardíacas , Mapeo Epicárdico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polisomnografía , Estudios Prospectivos , Radiografía Intervencional , Recurrencia , Reoperación , Apnea Obstructiva del Sueño/terapia , Ultrasonografía Intervencional
5.
Circ J ; 81(2): 235-240, 2017 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-28003574

RESUMEN

BACKGROUND: Sodium bicarbonate and ascorbic acid have been proposed to prevent contrast-induced nephropathy (CIN). The present study evaluated the effect of their combined use on CIN incidence.Methods and Results:We prospectively enrolled 429 patients with chronic kidney disease (CKD: baseline estimated glomerular filtration rate <60 mL/min/1.73 m2) prior to elective coronary catheterization. CIN was defined as absolute (≥0.5 mg/dL) or relative (≥25%) increase in serum creatinine within 72 h. In the saline hydration (n=218) and combined sodium bicarbonate+ascorbic acid (n=211) groups, a total of 1,500-2,500 mL 0.9% saline was given before and after the procedure. In addition, the combination group received 20 mEq sodium bicarbonate and 3 g ascorbic acid i.v. before the procedure, followed by 2 g ascorbic acid after the procedure and a further 2 g after 12 h. There were no significant differences between the basic characteristics and contrast volume in the 2 groups. CIN occurred in 19 patients (8.7%) in the saline group, and in 6 patients (2.8%) in the combined treatment group (P=0.008). CONCLUSIONS: Combined sodium bicarbonate and ascorbic acid could prevent CIN following catheterization in CKD patients.


Asunto(s)
Ácido Ascórbico/uso terapéutico , Medios de Contraste/efectos adversos , Nefrosis/prevención & control , Insuficiencia Renal Crónica/complicaciones , Bicarbonato de Sodio/uso terapéutico , Anciano , Anciano de 80 o más Años , Cateterismo Cardíaco , Creatinina/sangre , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nefrosis/inducido químicamente , Insuficiencia Renal Crónica/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA